UNSPSC 51385002: Isoprazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H18N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LB0T3NEB48, chemically known as 1-propanone, 1-(4-amino-2-methyl-5-phenylpyrrol-3-yl)-2-methyl- but generally known as isoprazone, which bears US NIH Compound Identifier 71737. European Medicines Agency schedules Isoprazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08328MIG. The term ISOPRAZONE is an International Non-Proprietary Name.

UNSPSC 51385002 Isoprazone is a Commodity code that encompasses pharmaceutical and medical supply procurement by state and local health agencies, though the recent solicitation activity under this code does not align directly with isoprazone itself but rather reflects broader pharmaceutical acquisition patterns by public health systems. State and local governments use this code to procure naloxone, drug deactivation systems, generic pharmaceuticals, and over-the-counter products through competitive processes that include RFPs, RFQs, and cooperative purchasing agreements. Issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate purchasing alliances such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which coordinate procurement for participating state and local government facilities across multiple jurisdictions. These agencies source through authorized drug wholesalers and manufacturers, with contracts typically requiring compliance with cGMP and FDA standards, E-Verify employment verification, workers' compensation and professional liability insurance, and adherence to federal drug supply chain regulations.

Recent activity concentrates in Florida and Texas, with broader multistate reach through cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building and a response deadline of July 26, 2023 (note: date discrepancy in source). The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capability information for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at improving prescription fulfillment efficiency and cost management, reflecting exploratory procurement strategy rather than a formal award. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026, with responses due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with evaluation weighted 75 percent on price competitiveness and the remainder on fixed pricing, administrative compliance, EDI capability, and administrative fee agreement. Vendors awarded to MMCAP must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, or Morris & Dickson) and pay a 3 percent administrative fee on contract purchases.